Journal of Orthopaedic Trauma · Nov 17, 2026
Menopausal Hormone Therapy History is Associated with Improved Postoperative Ambulatory Recovery in Postmenopausal Women with Hip Fragility Fractures
By Fox BQ, Kocher SD, Brown C et al.
OBJECTIVES: To compare changes in ambulatory status after hip fracture surgery in women with and without a history of systemic menopausal hormone therapy (MHT) use. METHODS: Design: Retrospective cohort Setting: Single center academic Level 1 trauma center Patient Selection Criteria: Patients were included if they were female, >=50, received surgery for OTA/AO 31-A (intertrochanteric/peritrochanteric), 31-B (femoral neck), and 32-A (subtrochanteric) fragility fractures from December 2022 to September 2025, and had minimum 3-month follow-up data. Outcome Measures and Comparisons: Patients were categorized into “Ever User” and “Never User” groups based on MHT exposure documented in electronic records. Primary outcomes were postoperative ambulatory status, categorized using a six-level functional scale, and return to baseline ambulation, measured as a binary variable at 30 and 90 days postoperatively. Secondary outcomes included 30- and 90-day hospital readmission and six-month all-cause mortality. Comparisons of outcomes were made between cohorts following adjustment for age, American Society of Anesthesiologists (ASA) grade, baseline ambulatory status, and dementia diagnosis. RESULTS: Among 358 included female patients, Ever Users (n=80) and Never Users (n=278) demonstrated similar ages (mean:80.6, range:60-100 vs. mean:78.8, range:50-101; P =0.14) and baseline ambulatory independence (48.8% vs. 46.0%, P =0.76). At 30 days, cohorts demonstrated similar rates of return to baseline function (25.3% vs. 23.4%; P =0.85). At 90 days, Ever Users demonstrated higher rates of independent ambulation (17.5% vs. 9.1%; P =0.029) and return to baseline status (53.8% vs. 35.8%; P <0.01). Thirty-day readmissions were less common among Ever Users (3.8% vs. 16.5%; P =0.0026), while 90-day readmission (23.8% vs. 21.6%; P =0.80) and six-month mortality (13.8% vs. 14.7%; P=0.97) were similar between groups. After adjustment for age, ASA grade, baseline ambulatory status, and dementia, MHT history was independently associated with 90-day return to baseline status (aOR 2.7, 95% CI 1.6–4.6, P <0.001). CONCLUSIONS: In women undergoing fragility hip fracture surgery, history of menopausal hormone therapy use was independently associated with improved return to baseline ambulation by 90 days postoperatively. These findings suggested prior menopausal hormone therapy exposure may confer functional benefits extending beyond fracture prevention. LEVEL OF EVIDENCE: III (Retrospective Cohort Study)
doi.org/10.1097/bot.0000000000003311PubMed 43042659Populations